BioMed
BioMed Central (BMC) is a United Kingdom-based, for-profit scientific open access publisher that produces over 250 scientific journals. All its journals are published online only. BioMed Central describes itself as the first and largest open access science publisher. It was founded in 2000 and has been owned by Springer, now Springer Nature, since 2008.
Beyond's analysis on BioMed
- — Harbour BioMed gains Stock Connect eligibility, expanding access to mainland Chinese investors
- — Harbour BioMed appoints Dr. Bob Zhang to lead metabolic disease franchise, signaling strategic focus on expanding therapeutic pipeline beyond immunology and oncology
- — Harbour BioMed and Sinopharm launch joint innovation R&D consortium to accelerate antibody therapeutic development
- — Harbour BioMed posts seventh straight profitable half‑year with positive profit alert for 2026 interim results
- — Harbour BioMed and Kelun-Biotech secure NMPA IND clearance for HBM7575/SKB575, advancing a novel asthma biologic into clinical trials in China
Recent news mentioning BioMed
- — Europe cannot afford to lose the race for biomedical innovation
- — Harbour BioMed Successfully Included in the Stock Connect, Reinforcing Capital Market Recognition
- — Haier Biomedical met en avant ses solutions de stockage biologique automatisé et ses solutions pharmaceutiques connectées lors de l'ISPE Singapore 2026
- — Haier Biomedical präsentiert automatisierte Biolagerung und vernetzte Pharma-Lösungen auf der ISPE Singapore 2026
- — Haier Biomedical destaca sus soluciones automatizadas de bioalmacenamiento y farmacéuticas conectadas
- — Haier Biomedical Highlights Automated Biostorage and Connected Pharma Solutions at ISPE Singapore 2026
- — Haier Biomedical Highlights Automated Biostorage and Connected Pharma Solutions at ISPE Singapore 2026
- — Johnson & Johnson (JNJ) Taps Sail Biomedicines in Bid for CAR-T Edge Over Bristol Myers Squibb
- — Harbour BioMed Appoints Mr. Youchen Chen and Dr. Ian Y. Liu as Executive Directors
- — Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy
- — Generate Biomedicines stock jumps as post-IPO lock-up set to expire
- — BiomEdit Acquires Folium Science Technology and Pipeline Assets to Expand Programmable Veterinary Biologics Capabilities